Standard Tigecycline Dosing Guidelines
Tigecycline, an IV glycylcycline antibiotic for complicated infections, uses fixed dosing regardless of patient weight. Adults receive 100 mg IV loading dose, followed by 50 mg IV every 12 hours. No adjustments for body weight, obesity, or changes like weight gain/loss appear in FDA-approved labeling or standard references.[1][2]
Adjustments for Specific Conditions
Dosing changes only for renal or hepatic impairment, not weight:
- No adjustment for renal issues, including dialysis.
- Reduce maintenance dose to 25 mg every 12 hours for severe hepatic impairment (Child-Pugh C).[1][3]
| Condition | Adjustment |
|-----------|------------|
| Normal renal/hepatic function | None (fixed 100 mg load, 50 mg q12h) |
| Mild-moderate hepatic impairment | None |
| Severe hepatic impairment | 100 mg load, then 25 mg q12h |
| Renal impairment/dialysis | None |
Evidence from Pharmacokinetics and Studies
Tigecycline's volume of distribution (7-10 L/kg) leads to lower exposure in obese patients (BMI >30), with AUC dropping up to 29% in those >100 kg. Despite this, trials like ATTENTION and studies in critically ill patients used fixed dosing without weight-based changes, prioritizing safety over PK optimization.[4][5] Retrospective data show similar clinical outcomes in obese vs. non-obese groups, though higher failure rates occur with low serum levels in heavy patients.[6]
Clinical Recommendations for Weight Changes
Guidelines (IDSA, FDA) do not recommend adjusting for weight fluctuations. In obesity or critical illness with edema/ascites:
- Some clinicians monitor trough levels (>0.5-1 mcg/mL) and consider 100 mg q12h empirically, but this is off-label.[7]
- No routine adjustment for weight loss/gain post-initiation.
Why No Weight-Based Dosing?
Fixed dosing simplifies hospital use and avoids toxicity risks from higher exposure in low-weight patients. PK variability exists, but efficacy data support the standard regimen across weights up to ~150 kg.[5][8]
[1]: Tygacil (tigecycline) Prescribing Information, Pfizer
[2]: Drugs.com - Tigecycline Dosage
[3]: FDA Label for Tygacil
[4]: Clin Pharmacokinet 2014;53:231–241
[5]: Crit Care Med 2013;41:1731–1737
[6]: Obesity (Silver Spring) 2011;19:2396–2401
[7]: Pharmacotherapy 2012;32:129–132
[8]: DrugPatentWatch.com - Tigecycline Patents (no weight-adjustment claims noted)